CL2025002505A1 - Compuestos derivados de pirazolopirimidina inhibidores del inflamasoma nlrp3. - Google Patents

Compuestos derivados de pirazolopirimidina inhibidores del inflamasoma nlrp3.

Info

Publication number
CL2025002505A1
CL2025002505A1 CL2025002505A CL2025002505A CL2025002505A1 CL 2025002505 A1 CL2025002505 A1 CL 2025002505A1 CL 2025002505 A CL2025002505 A CL 2025002505A CL 2025002505 A CL2025002505 A CL 2025002505A CL 2025002505 A1 CL2025002505 A1 CL 2025002505A1
Authority
CL
Chile
Prior art keywords
inhibit
nlrp3 inflammasome
derivative compounds
pyrazolopyrimidine derivative
pharmaceutically acceptable
Prior art date
Application number
CL2025002505A
Other languages
English (en)
Spanish (es)
Inventor
Ohba Yusuke
Adachi Kaoru
Sakurai Kentaro
Sato Shimpei
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CL2025002505A1 publication Critical patent/CL2025002505A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CL2025002505A 2023-02-24 2025-08-20 Compuestos derivados de pirazolopirimidina inhibidores del inflamasoma nlrp3. CL2025002505A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2023027432 2023-02-24

Publications (1)

Publication Number Publication Date
CL2025002505A1 true CL2025002505A1 (es) 2025-11-14

Family

ID=92501386

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025002505A CL2025002505A1 (es) 2023-02-24 2025-08-20 Compuestos derivados de pirazolopirimidina inhibidores del inflamasoma nlrp3.

Country Status (13)

Country Link
EP (1) EP4671247A1 (https=)
JP (2) JP7737490B2 (https=)
KR (1) KR20250151389A (https=)
CN (1) CN120752239A (https=)
AR (1) AR131919A1 (https=)
AU (1) AU2024226032A1 (https=)
CL (1) CL2025002505A1 (https=)
CO (1) CO2025011311A2 (https=)
IL (1) IL322520A (https=)
MX (1) MX2025009965A (https=)
PE (1) PE20252572A1 (https=)
TW (1) TW202448887A (https=)
WO (1) WO2024177127A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025140708A1 (zh) * 2023-12-31 2025-07-03 杭州百新生物医药科技有限公司 吡唑并嘧啶类化合物及其医药用途
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20191679T1 (hr) * 2013-10-30 2019-12-13 Shanghai hengrui pharmaceutical co ltd Derivati pirazolopirimidona ili pirolotriazona, postupak pripreme jednakih i njihove farmaceutske uporabe
WO2017205766A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2020150114A1 (en) * 2019-01-14 2020-07-23 Innate Tumor Immunity, Inc. Heterocyclic nlrp3 modulators, for use in the treatment of cancer
US12391675B2 (en) * 2019-01-14 2025-08-19 Innate Tumor Immunity, Inc. NLRP3 modulators
CN114829345A (zh) * 2019-12-27 2022-07-29 日本烟草产业株式会社 酰基磺酰胺化合物及其医药用途
US20240382488A1 (en) * 2021-03-29 2024-11-21 Halia Therapeutics, Inc. Nek7 inhibitors
WO2022216680A1 (en) * 2021-04-05 2022-10-13 Halia Therapeutics, Inc. Nek7 inhibitors
CA3229401A1 (en) * 2021-08-31 2023-03-09 Japan Tobacco Inc. 6-aminopyrazolopyrimidine compounds and medical use thereof
US20250114361A1 (en) * 2022-08-29 2025-04-10 Japan Tobacco Inc. Pyrazolopyrimidine compound and pharmaceutical use thereof
KR20250170647A (ko) * 2023-04-14 2025-12-05 다케다 야쿠힌 고교 가부시키가이샤 Nlrp3 억제제로서의 피라졸로피리미딘 유도체

Also Published As

Publication number Publication date
KR20250151389A (ko) 2025-10-21
CO2025011311A2 (es) 2025-09-08
AU2024226032A1 (en) 2025-09-11
AR131919A1 (es) 2025-05-14
EP4671247A1 (en) 2025-12-31
JP7737490B2 (ja) 2025-09-10
TW202448887A (zh) 2024-12-16
CN120752239A (zh) 2025-10-03
JP2025176085A (ja) 2025-12-03
IL322520A (en) 2025-10-01
MX2025009965A (es) 2025-09-02
PE20252572A1 (es) 2025-10-28
JP2024120882A (ja) 2024-09-05
WO2024177127A1 (ja) 2024-08-29

Similar Documents

Publication Publication Date Title
CL2025002505A1 (es) Compuestos derivados de pirazolopirimidina inhibidores del inflamasoma nlrp3.
CO2026004076A2 (es) Compuestos macrocíclicos, método de preparación de estos y uso de estos
CO2022003782A2 (es) Inhibidores de kras g12d
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
CO2023008167A2 (es) Inhibidores de prmt5
DOP2025000288A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CO2026004964A2 (es) Moduladores de kras
MX2024010399A (es) Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias
AR119207A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
CO2022017622A2 (es) Inhibidores de quinasa nek7
CL2019001077A1 (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer.
CO2024015820A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
UY30912A1 (es) Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso.
CO2024015816A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
BR112023019435A2 (pt) Inibidores de nek7
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
MX2024008629A (es) Derivados del azaindol y su uso como inhibidores de la erk-cinasa.
CO2022019131A2 (es) Inhibidores de la quinasa nek7
ECSP22049160A (es) Derivados de bencimidazol
UY40457A (es) Inhibidores de tead y métodos de uso de los mismos
CL2024002379A1 (es) Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
MX2021011979A (es) Derivados del isocromeno como inhibidores de la fosfoinositida 3-cinasa.
ECSP23075535A (es) Compuestos cíclicos y métodos de uso